Skip to main content

Advertisement

Fig. 2 | Journal of Translational Medicine

Fig. 2

From: Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers—results of a dose escalation trial

Fig. 2

Pharmacodynamics: mobilization of immature hematopoietic cells. a, b Dose-dependent mobilization of phenotypically (CD34+ , panel a) or functionally (CFU-C, panel b) defined stem and progenitor cells (HSPCs). HSPC mobilization was observed at all dose levels. Mobilization at the lowest dose level peaked 1 h after the end of the infusion and was delayed after higher doses. Dose dependence was observed for the first three dosing steps (n = 3–6, mean ± SEM). c The ratio between circulating CD34+ cells and CFU-C is shown for all doses. Clonogenicity of balixafortide mobilized CD34+ tended to be lower than for G-CSF mobilized CD34+ cells. Symbols represent individual values, the short horizontal bar and whiskers mean ± SEM. n = 3–6

Back to article page